View in EDS

Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab.

Saved in:
Bibliographic Details
Title: Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab.
Authors: Kim DK; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea., Synn CB; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Lee W; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Jo HN; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Lee CY; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Lee S; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea., Hwang JY; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Kim Y; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Kang SS; JEUK Institute for Cancer Research, JEUK Co., Ltd., Gumi-City, Republic of Korea., Baek S; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Na K; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Yang SM; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Kim MH; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Han H; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Han YJ; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Kim JH; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Park SY; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Park YJ; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Lee GT; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Choi SJ; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Sohn JO; Wide River Institute of Immunology, Seoul National University, Hongcheon, Republic of Korea., Ye SK; Wide River Institute of Immunology, Seoul National University, Hongcheon, Republic of Korea.; Department of Pharmacology and Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea., Lee JB; Division of Medical Oncology, Department of Internal Medicine and Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea., Lim SM; Division of Medical Oncology, Department of Internal Medicine and Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea., Hong MH; Division of Medical Oncology, Department of Internal Medicine and Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea., Pyo KH; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.; Yonsei New Il Han Institute for Integrative Lung Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea.; Department of Research Support, Yonsei Biomedical Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Cho BC; Division of Medical Oncology, Department of Internal Medicine and Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.; Yonsei New Il Han Institute for Integrative Lung Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea.
Source: Molecular cancer therapeutics [Mol Cancer Ther] 2025 Mar 04; Vol. 24 (3), pp. 354-369.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39632711
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kim+DK%22">Kim DK</searchLink>; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Synn+CB%22">Synn CB</searchLink>; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lee+W%22">Lee W</searchLink>; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Jo+HN%22">Jo HN</searchLink>; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lee+CY%22">Lee CY</searchLink>; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lee+S%22">Lee S</searchLink>; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Hwang+JY%22">Hwang JY</searchLink>; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kim+Y%22">Kim Y</searchLink>; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kang+SS%22">Kang SS</searchLink>; JEUK Institute for Cancer Research, JEUK Co., Ltd., Gumi-City, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Baek+S%22">Baek S</searchLink>; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Na+K%22">Na K</searchLink>; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Yang+SM%22">Yang SM</searchLink>; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kim+MH%22">Kim MH</searchLink>; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Han+H%22">Han H</searchLink>; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Han+YJ%22">Han YJ</searchLink>; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kim+JH%22">Kim JH</searchLink>; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Park+SY%22">Park SY</searchLink>; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Park+YJ%22">Park YJ</searchLink>; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lee+GT%22">Lee GT</searchLink>; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Choi+SJ%22">Choi SJ</searchLink>; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Sohn+JO%22">Sohn JO</searchLink>; Wide River Institute of Immunology, Seoul National University, Hongcheon, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Ye+SK%22">Ye SK</searchLink>; Wide River Institute of Immunology, Seoul National University, Hongcheon, Republic of Korea.; Department of Pharmacology and Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lee+JB%22">Lee JB</searchLink>; Division of Medical Oncology, Department of Internal Medicine and Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lim+SM%22">Lim SM</searchLink>; Division of Medical Oncology, Department of Internal Medicine and Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Hong+MH%22">Hong MH</searchLink>; Division of Medical Oncology, Department of Internal Medicine and Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Pyo+KH%22">Pyo KH</searchLink>; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.; Yonsei New Il Han Institute for Integrative Lung Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea.; Department of Research Support, Yonsei Biomedical Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Cho+BC%22">Cho BC</searchLink>; Division of Medical Oncology, Department of Internal Medicine and Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.; Yonsei New Il Han Institute for Integrative Lung Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101132535%22">Molecular cancer therapeutics</searchLink> [Mol Cancer Ther] 2025 Mar 04; Vol. 24 (3), pp. 354-369.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%2C+Inc%22">American Association for Cancer Research, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101132535 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1538-8514 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215357163%22">15357163 </searchLink><i>NLM ISO Abbreviation: </i>Mol Cancer Ther <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39632711
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1535-7163.MCT-24-0501
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 354
    Titles:
      – TitleFull: Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kim DK
      – PersonEntity:
          Name:
            NameFull: Synn CB
      – PersonEntity:
          Name:
            NameFull: Lee W
      – PersonEntity:
          Name:
            NameFull: Jo HN
      – PersonEntity:
          Name:
            NameFull: Lee CY
      – PersonEntity:
          Name:
            NameFull: Lee S
      – PersonEntity:
          Name:
            NameFull: Hwang JY
      – PersonEntity:
          Name:
            NameFull: Kim Y
      – PersonEntity:
          Name:
            NameFull: Kang SS
      – PersonEntity:
          Name:
            NameFull: Baek S
      – PersonEntity:
          Name:
            NameFull: Na K
      – PersonEntity:
          Name:
            NameFull: Yang SM
      – PersonEntity:
          Name:
            NameFull: Kim MH
      – PersonEntity:
          Name:
            NameFull: Han H
      – PersonEntity:
          Name:
            NameFull: Han YJ
      – PersonEntity:
          Name:
            NameFull: Kim JH
      – PersonEntity:
          Name:
            NameFull: Park SY
      – PersonEntity:
          Name:
            NameFull: Park YJ
      – PersonEntity:
          Name:
            NameFull: Lee GT
      – PersonEntity:
          Name:
            NameFull: Choi SJ
      – PersonEntity:
          Name:
            NameFull: Sohn JO
      – PersonEntity:
          Name:
            NameFull: Ye SK
      – PersonEntity:
          Name:
            NameFull: Lee JB
      – PersonEntity:
          Name:
            NameFull: Lim SM
      – PersonEntity:
          Name:
            NameFull: Hong MH
      – PersonEntity:
          Name:
            NameFull: Pyo KH
      – PersonEntity:
          Name:
            NameFull: Cho BC
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 04
              M: 03
              Text: 2025 Mar 04
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1538-8514
          Numbering:
            – Type: volume
              Value: 24
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Molecular cancer therapeutics
              Type: main
ResultId 1